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Background: Angiographic no reflow and decreased microvascular perfusion after percutaneous coronary intervention increase morbidity and 
mortality in ST-elevation myocardial infarction patients. ADAMTS13 is a metalloprotease that cleaves von Willebrand factor, thereby reducing its 
prohemostatic properties. There is considerable evidence that ADAMTS-13 levels decrease and von Willebrand factor levels increase in STEMI 
patients. Recombinant ADAMTS13 has been effective in reducing cerebral infarct size in a murine model of stroke. In this study recombinant 
ADAMTS13 was tested as a potential treatment of no reflow in a porcine model of cardiac ischemia and reperfusion.
methods: In 23 female swine (median age 83 days, median weight 30 kg) a balloon was inflated in the the circumflex coronary artery for 75 
minutes. Fifteen minutes after reperfusion, an intracoronary bolus of either recombinant ADAMTS13 (400 U/kg, Baxter Innovations Vienna, Austria) or 
vehicle was given.
results: ADAMTS13 activity significantly increased in treated pigs (median 18%, IQR 14.5-24.0 to median 324%, IQR 117.0-384.0, p= 0.003) 
whereas no change was observed in the control group. Animals were sacrificed seven days later for histopathology. There was no difference in the 
size of myocardial necrosis as assessed with plasma Troponin T measurements, continuous 12 leads ECG, macroscopical infarct analysis, and 
histopathology using phosphotungstic acid-hematoxylin staining. Microvascular obstruction as estimated by staining with anti-CD31/Hematoxylin 
and counting of vessels and microthrombi was similar for both groups.
conclusions: Intracoronary treatment with recombinant ADAMTS13 did not prevent formation of microthrombi or decrease infarct size in this 
porcine coronary model of ischemia and reperfusion.
